S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'

OptiNose (OPTN) Stock Price, News & Analysis

$1.46
-0.02 (-1.35%)
(As of 03/28/2024 ET)
Today's Range
$1.41
$1.50
50-Day Range
$1.21
$1.94
52-Week Range
$0.90
$2.10
Volume
399,834 shs
Average Volume
1.00 million shs
Market Capitalization
$164.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

OptiNose MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
174.0% Upside
$4.00 Price Target
Short Interest
Healthy
2.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.10
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$138,078 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.26) to ($0.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

96th out of 939 stocks

Pharmaceutical Preparations Industry

36th out of 444 stocks

OPTN stock logo

About OptiNose Stock (NASDAQ:OPTN)

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

OPTN Stock Price History

OPTN Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
OptiNose (NASDAQ:OPTN) Receives "Buy" Rating from HC Wainwright
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
OptiNose: Q4 Earnings Snapshot
OptiNose's Earnings: A Preview
3 Pharma Stocks to Consider for March Gains
See More Headlines
Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
NASDAQ:OPTN
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+174.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-35,480,000.00
Pretax Margin
-49.99%

Debt

Sales & Book Value

Annual Sales
$70.99 million
Book Value
($0.77) per share

Miscellaneous

Free Float
110,174,000
Market Cap
$164.47 million
Optionable
Not Optionable
Beta
-0.21
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

OPTN Stock Analysis - Frequently Asked Questions

Should I buy or sell OptiNose stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPTN shares.
View OPTN analyst ratings
or view top-rated stocks.

What is OptiNose's stock price target for 2024?

3 Wall Street research analysts have issued 1 year price objectives for OptiNose's shares. Their OPTN share price targets range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 174.0% from the stock's current price.
View analysts price targets for OPTN
or view top-rated stocks among Wall Street analysts.

How have OPTN shares performed in 2024?

OptiNose's stock was trading at $1.29 on January 1st, 2024. Since then, OPTN shares have increased by 13.2% and is now trading at $1.46.
View the best growth stocks for 2024 here
.

When is OptiNose's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our OPTN earnings forecast
.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $19.87 million for the quarter, compared to analysts' expectations of $19.90 million. During the same quarter last year, the business posted ($0.17) earnings per share.

What guidance has OptiNose issued on next quarter's earnings?

OptiNose issued an update on its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.0 million-$13.0 million, compared to the consensus revenue estimate of $18.2 million.

What other stocks do shareholders of OptiNose own?
When did OptiNose IPO?

OptiNose (OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a number of institutional and retail investors. Top institutional shareholders include MVM Partners LLC (13.00%), Vanguard Group Inc. (3.72%), Vanguard Group Inc. (3.72%), Kingdon Capital Management L.L.C. (3.46%), Velan Capital Investment Management LP (3.38%) and Nantahala Capital Management LLC (2.80%). Insiders that own company stock include Anthony J Krick, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends
.

How do I buy shares of OptiNose?

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPTN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners